key: cord-0959302-6ronwwyv
authors: Velasco, María; Galín, Isabel; Casas, Luisa; Pérez-Fernández, Elia; Martínez-Ponce, Diana; González-Piñeiro, Beatriz; Castilla, Virgilio; Guijarro, Carlos
title: Impact of previous COVID-19 on immune response after a single dose of BNT162b2 SARS-CoV-2 vaccine
date: 2021-06-04
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofab299
sha: 2d46ab4ca190c803c764c6ee8580235e9d08be26
doc_id: 959302
cord_uid: 6ronwwyv

Immune response after a single-dose of BNT162b2 vaccine is markedly increased in subjects with previous SARS-CoV-2 infection, reaching similar IgG titers to those elicited by the full two-doses in naïve cases, and increased modestly after the second dose. These data may inform the priority of the boosting dose.

Vaccination against SARS-CoV-2 is proposed by the WHO as the main option, at the present time, to control the COVID-19 pandemic. However, limited vaccine supply reduces the ability to reach a substantial proportion of individuals and delay the expectations of herd immunity [1] . The standard vaccination protocol for mRNA vaccines includes a 2 dose vaccine administration 3-4 weeks apart [2] . In this setting, a strategy to use single-dose of mRNA vaccines for some individuals could accelerate the achievement of this goal. Data on immune responses to single-dose vaccination with BNT162b2 are limited to few observational studies with small number of patients [3] [4] [5] [6] . Moreover, impact of previous natural infection on vaccine response is not well known. We thus sought to evaluate the immune responses after the first and second m-RNA vaccine doses according to different groups of previous SARS-CoV-2 infection and clinical COVID-19 presentation.

A random sample of 642 health-care workers (HCW) enrolled in a previous hospitalwide seroprevalence study of 2,590 HCW (April-2020 and November-2020; [7] ) were invited to participate in this study, based on stratification of 3 groups according to their seropositive status in both surveys: 1) Naïve SARS-CoV-2 patients: Seronegative in both surveys; 2) Transient seropositivity: seropositive in first survey and negative in second survey and 3) Persistent seropositivity: seropositive in both surveys. Seropositive HCW were further classified according to the severity of the previous SARS-CoV-2 infection 1) asymptomatic;

2) moderate COVID-19, attended as out-patients; and 3) severe COVID-19: HCW that required hospital admission.

A blood sample from HCW who had received the first dose of the mRNA BNT162b2 vaccine (Pfizer/BioNTech) was obtained just before the administration of the second dose of vaccine (21 days after the first dose), and 3 weeks after the second dose.

A c c e p t e d M a n u s c r i p t 5 Previous SARS-CoV-2 infection was considered when SARS-CoV-2 RT-PCR or IgG were positive (regardless of symptoms) in the first seroprevalence survey.

The SARS-CoV-2 IgG assay used is a chemiluminescent immunoanalysis of microparticles (CMIA) used for the quantitative detection of IgG antibodies against the Spike protein (RBD domain) of the SARS CoV-2 virus (IgG-S) in the Architect system (ABBOTT Diagnostics) with a cut-off <50 arbitrary Units/ml (AU/ml).

Demographics were compared by univariate analysis using chi squared and the Student's t test. IgG-S titers were described as geometric mean, median interquartile range.

We used univariate non-parametric test, U Mann-Whitney and Kruskall-Wallis test, to compare IgG-S titers between groups. Multiple comparisons were adjusted by Bonferroni method. To compare change between first and second dose we use the non-parametric related sample test, Wilcoxon test.

To estimate the difference between subgroups, anti-spike IgG titer was log transformed and mixed linear regression models were performed (Supplemental Table 3 ).

Data were evaluated with the Statistical Package SPSS-17 (IBM Armonk, NewYork) and R 3.4.4 software (https://cran.r-project.org/bin/windows/base/old/3.4.4/.)

All participants signed written consent. The protocol was approved by the independent review board of our hospital.

A total of 642 HCW were invited to participate in the study, 641 accepted (99.8%) and follow-up was completed in 623 HCW (97.0%). Mean age was 45.8 (SD 10.7) years and 77.3% were women. There were not significant differences among the groups except for a lower percentage of tobacco use (14.8 vs 21.5%, p=0.029) and higher percentage of obesity (11.6 vs 6.2%, p=0.014) in patients who developed COVID-19 (Supplementary Table 1 Table 3 ). Boosting dose effect was lower for groups with a strong response to the first dose.

Our serological evaluation in HCW shows a dramatic differential response 3-weeks Although we have not assessed the presence of neutralizing antibodies, our results reinforce preliminary reports with a small number of cases [3] [4] [5] [6] . This robust serologic response is highly correlated to the presence of neutralizing antibodies [8] . However, at present, we have no data regarding the duration of the serologic response nor the degree of protection against SARS-CoV-2 infection.

Our work provides some additional interesting data. First, HCW who had lost their SARS-CoV-2 antibodies exhibited a lower response, that might be insufficient to provide SARS-CoV-2 protection [3, 8] . Conversely, the combination of clinical COVID-19 and the presence of anti-Spike-IgG SARS-COV-2 antibodies before vaccination are strong predictors A c c e p t e d M a n u s c r i p t 8 of a robust serologic response to a single dose of the mRNA vaccine. This response is of similar magnitude or higher than the one achieved by a 2-dose vaccination in naïve SARS-CoV-2 subjects. Our data suggest that the serologic response is close to saturation in seropositive patients after a single mRNA vaccine dose, as suggested by a limited boost response to a second dose of the vaccine.

There is current controversy about the most efficient strategy regarding the use of available vaccines in order to offer a wider population protection [9,10]. In this regard, results from the UK suggest a decrease of COVID-19 following a program of single dose vaccination [11] . In addition, this strategy may reduce the exacerbated clinical symptoms associated with the second dose in seropositive individuals [5] . Whether enhanced single dose mRNA vaccine-induced serologic response among previously seropositive individuals will show a lasting response as compared to boosted vaccines is currently unknown. As no trial has evaluated the medium-term protective effects of a single-dose mRNA protocol, health policy makers rely on surrogate markers such as SARS-CoV-2 seropositivity prior to vaccination, for this difficult decision [12] . Our results suggest that deferring the second dose of the vaccine to seropositive individuals with a predictable strong serologic response may not a high-risk strategy for them, offering the option for vaccination of other individuals at risk until a wider vaccine availability allows for a standard 3-4 week interval between mRNA vaccine doses, as this is the protocol that has been tested in clinical trials. If SARS-CoV-2 serology is available, seropositive patients may be offered a deferred boost vaccination.

Unfortunately, our serologic survey provided only qualitative information and we cannot provide estimation on vaccine response according to diferent levels of basal IgG titles. In circumstances where serology is unknown, previous COVID-19 severity may guide the selection of patients. M a n u s c r i p t A c c e p t e d M a n u s c r i p t 14 Figure 1 

Background document on the mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19: background document to the WHO interim recommendations for use of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, under emergency use listing

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals

Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

Binding and Neutralization Antibody

Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2

Hospital-Wide SARS-CoV-2 seroprevalence in health care workers in a Spanish teaching hospital

Effectiveness of First Dose of COVID

Vaccines Against Hospital Admissions in Scotland: National Prospective Cohort Study of

Million People

Model-informed COVID-19 vaccine prioritization strategies by age and serostatus

A c c e p t e d M a n u s c r i p t